Protalix Biotherapeutics Inc (NYSEMKT:PLX) investors are getting skittish today, sending shares on a roughly 5% whirl down despite the biotech firm posting a …
Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced its financial results for the six months ended June 30, 2017 and provided a corporate update. “Substantial progress was …
Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced today that phase II trial results, including new clinical data, for alidornase alfa (PRX-110) for the treatment of …
Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced that a Supplemental New Drug Application (sNDA) submitted to the U.S.
In a research report released Monday, Rodman & Renshaw analyst Ram Selvaraju reiterated a Buy rating on shares of Protalix Biotherapeutics Inc (NYSEMKT:PLX) with …
Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced that the FDA cleared an Investigational New Drug application (IND) for a clinical trial evaluating the safety and efficacy …
Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced positive results from the Company’s phase II clinical trial of alidornase alfa for the treatment of Cystic Fibrosis …
Protalix Biotherapeutics Inc (NYSEMKT:PLX) shares surged nearly 10% in Friday’s trading session, after Canadian specialty pharmaceutical firm Knight Therapeutics announced that it has acquired 6,200,000 common shares of …
Protalix BioTherapeutics Inc. (NYSEMKT:PLX) positive clinical study results from the Company’s Phase I trial of PRX-106, an orally administered plant cell-expressed recombinant anti-TNF fusion …
